Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Technology and Dementia Preconference.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Circulating neprilysin clears brain amyloid.

Molecular and cellular neurosciences·2010

Same author

Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease.

Molecular therapy : the journal of the American Society of Gene Therapy·2009

Search research articles

Related Experiment Video

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

Technology and Dementia Preconference.

Christa Studzinski¹

¹Ontario Brain Institute, Toronto, ON, Canada.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association

|December 23, 2025

Summary

Wearable technology adoption for aging individuals with dementia is limited. The CORTEX program empowers community groups to test and scale neurotechnologies, improving dementia care and outcomes.

Area of Science:

Neurotechnology
Gerontology
Digital Health

Background:

Widespread adoption of wearable technologies for aging individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD) remains a challenge.
This limits the potential of wearables to transform dementia care and improve patient outcomes.
The Ontario Brain Institute developed the CORTEX program to address this gap.

Purpose of the Study:

To share lessons learned from co-designing and launching the CORTEX program.
To demonstrate how community involvement can facilitate the testing, implementation, and scaling of wearable technology.
To outline the development of the Canadian Dementia Registry as a flagship initiative.

Main Methods:

Co-designing the CORTEX program with community groups and individuals with lived experience.

More Related Videos

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

Transcranial Pulse Stimulation for Alzheimer's Patients

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Related Experiment Videos

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

Transcranial Pulse Stimulation for Alzheimer's Patients

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

Conducting initial pilot studies in partnership with patient groups.

Leveraging learnings to launch the Canadian Dementia Registry in collaboration with the Alzheimer Society of Ontario.

Main Results:

The CORTEX program empowers community groups to test and scale neurotechnologies.
The Canadian Dementia Registry facilitates understanding of the early dementia journey and diagnosis.
Neurotechnologies are being tested in diverse populations against clinically relevant scales.

Conclusions:

Community-led initiatives like CORTEX are crucial for the adoption of wearable technology in dementia care.
The Canadian Dementia Registry enhances early detection and integrates neurotechnology into community care pathways.
This approach aims to improve access to timely and appropriate care for individuals with dementia.